Table S1: SNP-specific estimates for statin, PCSK9 inhibitor and ezetimibe SNPs on LDL-cholesterol (effect size) in women and men from the UK Biobank, and for comparison estimates for both sexes together from the Global Lipids Genetics Consortium (GLGC) [1].

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Therapy | Sex | Source | SNP | Effect allele | beta | se | p-value | F-statistic |
| Statin | Women | UK Biobank | rs12916 | C | 0.0695 | 0.0033 | 3.2E-100 | 452.2 |
|  | Men | UK Biobank |  |  | 0.0527 | 0.0036 | 2.5E-49 | 218.2 |
|  | All | GLGC |  |  | 0.0733 | 0.0038 | 7.8E-78 | na |
| PCSK9  | Women | UK Biobank | rs11206510 | T | 0.0501 | 0.0041 | 2.7E-34 | 149.2 |
| inhibitor | men | UK Biobank |  |  | 0.0454 | 0.0045 | 2.9E-24 | 103.3 |
|  | All | GLGC |  |  | 0.0831 | 0.005 | 2.4E-53 | na |
|  | Women | UK Biobank | rs2149041 | G | 0.0414 | 0.0041 | 8.1E-24 | 101.3 |
|  | Men | UK Biobank |  |  | 0.0439 | 0.0045 | 1.7E-22 | 95.2 |
|  | All | GLGC |  |  | 0.0636 | 0.0049 | 1.4E-35 | na |
|  | Women | UK Biobank | rs7552841 | T | 0.0260 | 0.0034 | 2.7E-14 | 57.9 |
|  | Men | UK Biobank |  |  | 0.0207 | 0.0037 | 3.0E-08 | 30.7 |
|  | All | GLGC |  |  | 0.0368 | 0.0044 | 5.4E-15 | na |
| Ezetimibe | Women | UK Biobank | rs10260606\*  | C | 0.0407 | 0.0041 | 8.5E-23 | 96.6 |
|  | Men | UK Biobank |  |  | 0.0295 | 0.0045 | 6.9E-11 | 45.2 |
|  | All | GLGC |  |  | 0.0427 | 0.0427 | 3.3E-17 | na |

\* in place of rs2073547

Table S2: SNP-specific estimates for anakinra and tocilizumab on IL1-Ra [2] and IL-6 [3] respectively

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Therapy | Target | SNP | Effect allele | beta | se | F-statistic |
| Anakinra | IL-1Ra | rs6743376 | C | 0.25 | 0.025 | 100 |
|  |  | rs1542176 | C | 0.18 | 0.025 | 51.8 |
| Tocilizumab | IL-6 | rs7529229 | C | 0.09 | 0.005 | 3600 |

1. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, Ganna A, Chen J, Buchkovich ML, Mora S *et al*: **Discovery and refinement of loci associated with lipid levels**. *Nature genetics* 2013, **45**(11):1274-1283.

2. **Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis**. *Lancet Diabetes Endocrinol* 2015, **3**(4):243-253.

3. Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JE, Shah T, Sofat R, Guo Y, Chung C, Peasey A, Pfister R *et al*: **The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis**. *Lancet (London, England)* 2012, **379**(9822):1214-1224.